Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.

Item

http://www.wikidata.org/entity/Q35826691

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.

@ast

Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.

@en

type

Item

label

Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.

@ast

Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.

@en

prefLabel

Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.

@ast

Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients.

@en

P1476

Weight related differences in the pharmacokinetics of abacavir in HIV-infected patients

@en

P2093

D Salmon

http://www.w3.org/2001/XMLSchema#string

E Rey

http://www.w3.org/2001/XMLSchema#string

G Pons

http://www.w3.org/2001/XMLSchema#string

H Chappuy

http://www.w3.org/2001/XMLSchema#string

J Dimet

http://www.w3.org/2001/XMLSchema#string

J-M Tréluyer

http://www.w3.org/2001/XMLSchema#string

S Urien

http://www.w3.org/2001/XMLSchema#string

V Jullien

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetics of [(14)C]abacavir, a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor, administered in a single oral dose to HIV-1-infected adults: a mass balance study

Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt Study.

Ways to fit a PK model with some data below the quantification limit.

Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection.

Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators

Safety and pharmacokinetics of abacavir (1592U89) following oral administration of escalating single doses in human immunodeficiency virus type 1-infected adults

Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults

Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.

Multiple-dose pharmacokinetics and pharmacodynamics of abacavir alone and in combination with zidovudine in human immunodeficiency virus-infected adults.

Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex

P304

183-188

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2125.2004.02259.X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Nicolas Dupin

P577

2005-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8056144

http://www.w3.org/2001/XMLSchema#string

P698

15676040

http://www.w3.org/2001/XMLSchema#string

P932

1884744

http://www.w3.org/2001/XMLSchema#string